Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2017002 | 0.85 | AHCY (0.61) | AHCYADCY5 | |
| SCHEMBL2017000 | 0.85 | AHCY (0.61) | AHCYADCY5 | |
| SCHEMBL13458411 | 0.78 | AHCY (0.55) | AHCY | |
| SCHEMBL2018547 | 0.76 | AHCY (1.00) | AHCY | |
| SCHEMBL2023510 | 0.75 | AHCY (1.00) | AHCY | |
| SCHEMBL2026537 | 0.74 | AHCY (0.48) | AHCYADCY5 | |
| SCHEMBL2021176 | 0.72 | AHCY (0.46) | AHCYADCY5 | |
| SCHEMBL13458408 | 0.71 | AHCY (0.64) | AHCY | |
| SCHEMBL12573442 | 0.70 | AHCY (1.00) | AHCY | |
| SCHEMBL13457934 | 0.69 | AHCY (0.74) | AHCY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8629275-B2 | AHCY hydrolase inhibitors for treatment of hyper homocysteinemia | MERCK SHARP & DOHME CORP. (US) | 2014-01-14 | — | — | US | disclosed |
| US-8629275-B2 | AHCY hydrolase inhibitors for treatment of hyper homocysteinemia | MERCK SHARP & DOHME CORP. (US) | 2014-01-14 | — | — | US | disclosed |
| US-8629275-B2 | AHCY hydrolase inhibitors for treatment of hyper homocysteinemia | MERCK SHARP & DOHME CORP. (US) | 2014-01-14 | — | — | US | disclosed |
| US-20110160229-A1 | AHCY HYDROLASE INHIBITORS FOR TREATMENT OF HYPER HOMOCYSTEINEMIA | MERCK SHARP & DOHME CORP. | 2011-06-30 | — | — | US | disclosed |
| US-20110160229-A1 | AHCY HYDROLASE INHIBITORS FOR TREATMENT OF HYPER HOMOCYSTEINEMIA | MERCK SHARP & DOHME CORP. | 2011-06-30 | — | — | US | disclosed |
| US-20110160229-A1 | AHCY HYDROLASE INHIBITORS FOR TREATMENT OF HYPER HOMOCYSTEINEMIA | MERCK SHARP & DOHME CORP. | 2011-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160229-A1 | AHCY HYDROLASE INHIBITORS FOR TREATMENT OF HYPER HOMOCYSTEINEMIA | AHCY, AHCYL1, BHMT | AHCY 1/4885ADCY5 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.